✦ LIBER ✦

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis

✍ Scribed by Ghez, David; Micol, Jean-Baptiste; Pasquier, Florence; Auger, Nathalie; Saada, Véronique; Spentchian, Marc; Ianotto, Jean-Christophe; Bourhis, Jean-Henri; Bennaceur-Griscelli, Anelyse; Terré, Christine; Castaigne, Sylvie; Rigaudeau, Sophie; Rousselot, Philippe; de Botton, Stéphane

Book ID: 121308259
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 292 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.07.147

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical impact of dose reductions and i

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

✍ Fabio P. S. Santos; Hagop Kantarjian; Carmen Fava; Susan O’Brien; Guillermo Garc 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Restricted access to second generation t

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

✍ Paolo Gallipoli; Pat Shepherd; David Irvine; Mark Drummond; Tessa Holyoake 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB